Christina Chan
Contact
Email: krischan@msu.edu
Office Phone: 517-432-4530
View publications on MSU Scholars
IQ DIVISION – Biomedical Devices
Departmental AFFILIATIONS
- Chemical Engineering and Materials Science
- Biochemistry and Molecular Biology
- Computer Science and Engineering
- Biomedical Engineering
About
Christina Chan is the George Bissell Professor of Chemical Engineering, with joint appointments in the Department of Biochemistry and Molecular Biology and the Department of Computer Science and Engineering.
Since joining the faculty of MSU in 2002, she has published more than 130 journal articles, reviews, and book chapters. She was elected to the American Institute for Medical and Biological Engineering’s College of Fellows in 2012 and invited to the National Academy of Engineering “Frontiers in Engineering.”
Dr. Chan is a recipient of the AIChE Area Forum 15D/E Engineering Fundamentals in Life Science Award, Beal Outstanding Faculty Award (formerly University Distinguished Faculty Award), Withrow Distinguish Scholar Award, and Withrow Award for Excellence in Teaching. She serves on the editorial boards of Scientific Reports, Biotechnology and Bioengineering Journal, and is section editor and associate editor of several journals including BMC Systems Biology and Plos One.
Dr. Chan earned her B.S. in chemical engineering from Columbia University and her M.S. and Ph.D. in chemical and biochemical engineering from the University of Pennsylvania. She also spent eight years at DuPont prior to returning to academia and taking a post-doctoral position at the Center for Engineering in Medicine at the Harvard Medical School.
The Chan Lab
The Chan Lab is focused on understanding the signaling and regulatory mechanisms that are altered in diseases, such as obesity, Alzheimer’s disease, and cancer. Our group develops and applies metabolic engineering and systems biology approaches in combination with biochemical, biophysical, and molecular biology measurements and animal studies to identify targets and disease biomarkers. Our group also is developing polymeric-based drug delivery and tissue engineering platforms to modulate these pathways for treating these diseases.